Drug manufacturer TaiGen Biotechnology Co (太景生技) yesterday announced that it has inked a deal with ScinoPharm Taiwan (台灣神隆) to use the latter’s active pharmaceutical ingredients to make Burixafor, a stem cell mobilizer.
Under the deal, ScinoPharm is to manufacture the ingredients at its factory in Changshu, China, which began operating in December last year, as well as conduct the clinical trials for Burixafor.
Although the pact only goes as far as the clinical trial stage, the companies are likely to continue their partnership after the drug hits the market, TaiGen chief financial officer Max Chan (詹孟恭) said at a shareholders’ meeting.
TaiGen has completed phase two of the clinical trials it is conducting in the US for Burixafor, which covered the drug’s mobilization of stem cells for blood and marrow transplants, Chan said.
He added that TaiGen has also received approval from Chinese authorities to initiate phases one and two of clinical testing to determine if Burixafor can be used to enhance the effects of chemotherapy.
TaiGen chairman and CEO Hsu Ming-chu (許明珠) said she expects the China trials to require the participation of 50 to 60 subjects, adding that they are to be completed at the end of next year, with phase-three trials to be done by the end of the first half of 2017.
TaiGen is looking for partners to conduct phase-three trials in the US, she added.
Last year, the firm posted losses of NT$432.19 million (US$14.41 million), or NT$0.66 per share, down 10.69 percent from losses of NT$478.39 million, or NT$0.81 per share, the previous year on the back of higher revenue last year.
Citing data from JSB Market Research, Hsu said peak sales of Burixafor are projected to reach US$1.1 billion a year.
JSB predicts that with Burixafor, TaiGen will grab 40 percent of the market for blood and marrow transplant drugs, with sales of US$500 million a year, while staking out a 10 to 15 percent share of the chemotherapy enhancers market that would give TaiGen US$600 million in sales a year, Hsu said.
Chan said TaiGen is to spend NT$500 million to NT$600 million on research and development this year, more than NT$440.37 million it spent last year, but that it will remain in the red.
While some shareholders voiced concern that TaiGen’s share price is relatively low compared with its local peers, Hsu said the company will still stick to its principles of providing accurate forecasts and refraining from inflating its outlook.
“Taiwan’s stock market now is reminiscent of the US’ in the 1970s, when venture capitalists profited from incomplete information about listed drug companies,” she said. “However, when most investors learn how to properly evaluate a such firms, these venture capitalists can no longer turn a profit and only those companies with strong innovation and portfolios stay standing.”
Her remarks won support from some shareholders at the meeting.
“I do not think the CEO should change her style and follow the current trends in Taiwan,” said one, adding that he thinks TaiGen should focus on making high-quality drugs.
STRONG INTEREST: Analysts have pointed to optimism in TSMC’s growth prospects in the artificial intelligence era as the cause of the rising number of shareholders The number of people holding shares of chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) hit a new high last week despite a decline in its stock price, the Taiwan Depository and Clearing Corp (TDCC, 台灣集保) said. The number of TSMC shareholders rose to 2.46 million as of Friday, up 75,536 from a week earlier, TDCC data showed. The stock price fell 1.34 percent during the same week to close at NT$1,840 (US$57.55). The decline in TSMC’s share price resulted from volatility in global tech stocks, driven by rising international crude oil prices as the war against Iran continues. Dealers said
PRICE HIKES: The war in the Middle East would not significantly disrupt supply in the short term, but semiconductor companies are facing price surges for materials Taiwan’s semiconductor companies are not facing imminent supply disruptions of essential chemicals or raw materials due to the war in the Middle East, but surges in material costs loom large, industry association SEMI Taiwan said yesterday. The association’s comments came amid growing concerns that supplies of helium and other key raw materials used in semiconductor production could become a choke point after Qatar shut down its liquefied natural gas (LNG) production and helium output earlier this month due to the conflict. Qatar is the second-largest LNG supplier in the world and accounts for about 33 percent of global helium output. Helium is
Taiwan’s natural gas supply remains stable through the end of May, despite rising concerns about potential disruptions to Qatari liquefied natural gas (LNG) supplies due to escalating conflicts in the Middle East, the Ministry of Economic Affairs said yesterday. The ministry in a statement said that Taiwan has completed preparations for natural gas supply and shipping schedules through the end of May. It has also made plans to increase natural gas imports from regions outside the Middle East in June to ensure a stable supply, it added. Taiwan sources natural gas from 14 countries and is not solely dependent on the Middle East,
China is clamping down on fertilizer exports to protect its domestic market, industry sources said, putting an additional strain on global markets that were already grappling with shortages caused by the US-Israeli war on Iran. China is among the largest fertilizer exporters — shipping more than US$13 billion of it last year — and it has a history of controlling exports to keep prices low for farmers. Shipments through the war-blocked Strait of Hormuz account for about one-third of the sea-borne supply. This month, Beijing banned exports of nitrogen-potassium fertilizer blends and certain phosphate varieties, sources said. The ban, which has not